14th World Bispecific Summit 2023

Be at the forefront of the Bispecific space as it goes head to head with cell therapy to transform oncology. Among numerous innovations in cancer immunotherapy, Bispecific antibody treatments have never been more promising with continuous clinical updates and approvals over the last year, including the huge waves seen in multiple myeloma and lymphoma treatment.

The World Bispecific Summit returns for its 14th year with an enriched program boasting comprehensive coverage of all the key discovery, pre-clinical and clinical challenges including design, clinical, regulatory and combination strategies. Led by the industry's brightest minds from the likes of Sanofi, Regeneron, the FDA, Alligator Biosciences and Amgen, it's the perfect platform to celebrate wins, work through challenges and establish connections with the leading pharma, biotech and academic KOLs.

Deep dive into novel target selection, immune cell modulators, target selection and pre-clinical/clinical readouts and gain holistic insight on the current state-of-play in the bispecific landscape to supercharge your own pipeline from discovery through to IND approval.

URLs:
Website: https://go.evvnt.com/1780206-0?pid=10018
Tickets: https://go.evvnt.com/1780206-2?pid=10018
Brochure: https://go.evvnt.com/1780206-3?pid=10018
Twitter: https://go.evvnt.com/1780206-4?pid=10018
LinkedIn: https://go.evvnt.com/1780206-5?pid=10018

Prices:
Conference Only - Service Provider: USD 3599.00,
Conference + Seminar Day - Service Provider: USD 5696.00,
Conference Day Only - Academic Pricing: USD 2499.00,
Conference + Seminar Day - Academic Pricing: USD 3996.00,
Conference Only - Drug Developer: USD 2899.00,
Conference + Seminar Day - Drug Developer: USD 4696.00

Speakers: Alexander Schinagl, Chief Technology Officer, OncoOne, Anish Suri, President and Chief Scientific Officer, Cue Biopharma, Arne Scheu, Co-Founder and Chief Executive Officer, LiliumX, Christoph Rader, Chief Technology Officer, Aethon Therapeutics, Christopher Mehlin, Co-Founder and Chief Scientific Officer, Link Immunotherapeutics Inc., Colette Johnston, Vice President, Discovery, Crescendo Biologics, Daniel Bedinger, Application Science Manager, Carterra, Ercole Rao Group Leader - Biologics Research and Engineered Protein Therapeutics, Sanofi, Giorgio SALCIARINI, Marketing and Business Development Manager, BSP Pharmaceuticals, Hayretin Yumerefendi, Associate Director, Novartis, Johannes Nelke, Senior Scientist Bispecific Antibodies, BioNTech SE, John Burke President, Chief Executive Officer and Co-Founder Applied BioMath, Juha Punnonen, Chief Development Officer, Hinge Bio, Inc., Kara Olson, Fellow Scientist, Regeneron Pharmaceuticals Inc, Kartik Krishnan, Chief Medical Officer, OncoNano Medicine Inc., Ken Howard, Associate Professor and Group Leader - Interdisciplinary Nanoscience Centre (iNANO), Aarhus University, Kerry Casey, Associate Director - Precision Medicine, Regeneron Pharmaceuticals Inc, Marjorie Shapiro, Chief of Laboratory of Molecular and Developmental Immunology, US Food and Drug Administration (FDA), Mattias Levin Director - Antibody Technology Innovation, Alligator Bioscience AB, Michael Groaning, Global Medical Affairs Prostate Cancer and Early Solid Tumor Pipeline Assets Lead, Amgen Inc., Mingjiu Chen, Chief Executive Officer, Biosion, Mohamed-Reda Benmebarek, Postdoctoral Fellow, National Cancer Institute, Nimish Gera, Vice President - Biologics Mythic Therapeutics, Nina Weisser Director - Multispecific Antibody Therapeutics, Zymeworks, Qingcong Lin, Chief Executive Officer, Biocytogen Boston Corp, Raffi Tonikian, Director – Translational Biomarkers, Abcellera, Rakesh Dixit President, Chief Scientific Officer, Regio Biosciences, Shailee Patel, Research Analyst, Beacon Intelligence, Shu-Min Liu President and Chief Executive Officer, Shenzhen Enduring Biotech, Ltd., Takamitsu Hattori, Research Professor, NYU Grossman School of Medicine, Thomas Nittoli, Senior Director - ADCs, Regeneron Pharmaceuticals Inc, Tilman Schlothauer, Senior Principal Scientist, Roche, Upendra Katneni, Staff Fellow, US Food and Drug Administration (FDA)